Noetik Expands Scientific Advisory Board to Build the Future of Cancer Therapeutics

Audio By Carbonatix

SAN FRANCISCO--(BUSINESS WIRE)--Oct 1, 2025--

Noetik, an AI-native biotech company leveraging self-supervised machine learning and high-throughput spatial data to develop next-generation cancer therapeutics, announced today the appointment of five distinguished scientific leaders, Dr. Vijay Kuchroo, Dr. Matthew Albert, Dr. William Grossman, Dr. Marcia Belvin, and Dr. Kwok-Kin Wong, to its Scientific Advisory Board.

“We’ve assembled an extraordinary team of clinicians and scientists who bring diverse and complementary perspectives across immunology, oncology, clinical development, and translational medicine,” said Ron Alfa, M.D., Ph.D., CEO & Co-Founder, Noetik. “What excites us is not only their track record of translating science into real impact, but also their ability to challenge conventional thinking to help us build a radically new kind of therapeutic engine and execute clinical strategies that enhance the probability of success. Each of these leaders have operated at the interface of biology and technology, and deeply understand what it takes to go from idea to regulatory approval. We’re thrilled to welcome them as thought partners as we scale our platform and move our first programs toward the clinic.”

About the Appointees

Vijay Kuchroo Ph.D., DVM, is the Samuel L. Wasserstrom Professor of Neurology at Harvard Medical School, Senior Scientist at Brigham and Women’s Hospital, founding Director of the Gene Lay Institute for Immunology and Inflammation, and a core member of the Broad Institute and Klarman Cell Observatory. His pioneering work has reshaped understanding of T cell biology, immune tolerance, and the mechanisms of autoimmunity and cancer. He was the first to characterize the TIM family of immune regulatory genes, including TIM-3, now a major cancer immunotherapy target, and his lab identified Th17 cells, key drivers of autoimmune disease. These discoveries, along with widely used transgenic models, have laid the foundation for therapeutic advances in oncology, neurology, and inflammatory disorders.

Matthew Albert, M.D., Ph.D., is a physician-scientist with deep expertise in immunology, pathology, and translational science. He spent over 15 years leading a research group at the Institut Pasteur before joining Genentech’s Cancer Immunology Department, where he led a team focused on immuno-oncology drug development. Dr. Albert has also held senior roles at Insitro, where he served as Senior Vice President of Biology, and at HiBio, where as Chief Translational Officer he built a clinical immunology portfolio that led to the company’s acquisition. He is currently VP, Translational Sciences & Early Clinical Development at Octant.

William Grossman, M.D., Ph.D., brings more than 25 years of experience in oncology, including a clinical background in hematology, oncology, and bone marrow transplantation. He previously served as Professor and Division Director at the Medical College of Wisconsin before transitioning to leadership roles in industry. Dr. Grossman was most recently Senior Vice President and Therapeutic Area Head of Oncology at Gilead Sciences, and has also served as Chief Medical Officer at Arcus Biosciences and Bellicum Pharmaceuticals. His career also includes positions at Merck, AbbVie, Biothera, and Genentech/Roche. He currently serves on the Board of Directors of Day One Biopharmaceuticals and enGene, as well as the Biopharma Advisory Board at Ginkgo Bioworks.

Marcia Belvin, Ph.D., is a veteran cancer biologist and currently serves as Chief Scientific Officer at CytomX Therapeutics, where she oversees the company’s scientific strategy, translational studies, and preclinical portfolio. She spent more than a decade at Genentech, leading cross-functional teams in preclinical oncology and guiding programs from early discovery through IND-enabling studies. Her work spanned cancer signaling, cancer metabolism, and immuno-oncology, contributing to the development of multiple first-in-class therapeutic candidates. Earlier in her career, she held senior discovery roles at Exelixis, where she helped build a portfolio of targeted therapies.

Kwok-Kin Wong, M.D., Ph.D., is an internationally recognized physician-scientist and leader in thoracic oncology. He currently is a tenured professor of medicine of NYU Langone Health’s Perlmutter Cancer Center. Dr. Wong’s research has significantly advanced the understanding of lung cancer biology, particularly in the development and application of genetically engineered mouse models and the study of resistance mechanisms to targeted therapies. He previously held faculty positions at Dana-Farber Cancer Institute and Harvard Medical School, where he helped pioneer translational research efforts in non-small cell lung cancer.

The appointment of these translational and scientific leaders to Noetik’s Scientific Advisory Board strengthens the company’s commitment to building a world-class team, advancing its AI-native platform, and progressing its first therapeutic programs toward clinical development.

About Noetik

NOETIK is a frontier therapeutics company harnessing AI to deeply understand human biology and redefine clinical outcomes in oncology. Leveraging the largest proprietary multimodal oncology dataset of its kind, uniquely integrating spatial biology, NOETIK’s OCTO series of models (Oncology Counterfactual Therapeutics Oracle) precisely match therapeutic targets to patient subpopulations and accurately predict clinical efficacy. This AI-first approach elevates therapeutic development from probabilistic guesswork to precision science. By strategically partnering with clinical developers and in-licensing promising therapeutics, NOETIK accelerates the delivery of transformative cancer treatments to patients. To learn more about Noetik, visit https://www.noetik.ai

View source version on businesswire.com:https://www.businesswire.com/news/home/20251001739674/en/

CONTACT: Noetik Media

Thermal for Noetik

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: SOFTWARE RESEARCH GENERAL HEALTH PHARMACEUTICAL ONCOLOGY TECHNOLOGY ARTIFICIAL INTELLIGENCE GENETICS HEALTH TECHNOLOGY SCIENCE BIOTECHNOLOGY HEALTH

SOURCE: Noetik

Copyright Business Wire 2025.

PUB: 10/01/2025 08:00 AM/DISC: 10/01/2025 07:59 AM

http://www.businesswire.com/news/home/20251001739674/en